|
The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cervical Cancer.
RECRUITINGN/ASponsored by Chongqing University Cancer Hospital
Actively Recruiting
PhaseN/A
SponsorChongqing University Cancer Hospital
Started2023-08-25
Est. completion2027-07-01
Eligibility
Age18 Years – 70 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05749887
Summary
This is a single-center single-arm study. The main purpose of this study is to study the efficacy of surgical treatment for patients with locally advanced cervical cancer (FIGO IB3, IIA2-IVA) who still have residual tumor after concurrent radiotherapy and chemotherapy.
Eligibility
Age: 18 Years – 70 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria: 1. Stage Ib3 and IIA2-IVA (FIGO2018) cervical cancer with histopathology of squamous cell carcinoma, adenosquamous cell carcinoma, adenocarcinoma. 2. Complete standard CCRT(Pelvic EBRT+ concurrent platinum-containing chemotherapy+ brachytherapy). 3. After 4-12 weeks of treatment, the cervical biopsy pathology confirmed residual cancer, or the cervical biopsy was negative, but PET /CT showed that SUVmax of the residual lesions in the cervical and/or pelvic lymph nodes were ≥ 2.5, two or more gynaecological oncologists with Grade IV operation qualification and the title of deputy director or above have gynecological examination, and the multidisciplinary team(MDT) evaluation recommended surgical treatment. 4. ECOG score:0 \~ 1. 5. The expected survival time\>6 months; 6. There is no absolute contraindication of surgery and the patients with good compliance. Exclusion Criteria: 1. The radiotherapy and chemotherapy are not completed or the radiotherapy dose is not reached. 2. PET /CT and/or pathological indicates that there is a distant metastasis including para-aortic lymph nodes. 3. Other malignancies were diagnosed within five years or needed treatments. 4. History of important organ transplantation. 5. History of immune disease who need to take immunosuppressive drugs. 6. History of serious mental illness and brain functional disorder. 7. Drug abuse or drug use history. 8. Participants in other clinical trials at the same time. 9. Those who are unable or unwilling to accept surgical treatment/sign informed consent/comply with research requirements. 10. Without surgical conditions: 1) Chronic renal insufficiency or renal failure; 2) Liver insufficiency; 3)Chronic lung disease with restrictive respiratory dysfunction; 4) Cardiac dysfunction (patients with relative and absolute contraindications to surgery after consultation by cardiac physicians. 11. Patients who cannot understand the research regimen and refuse to sign the informed consent form. 12. Other concomitant diseases or special conditions seriously endanger the patient's health or interfere with the trial.
Conditions2
CancerCervical Cancer
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorChongqing University Cancer Hospital
Started2023-08-25
Est. completion2027-07-01
Eligibility
Age18 Years – 70 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05749887